Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
17
IDYA Quote, Financials, Valuation and Earnings
Last price:
$25.04
Seasonality move
:
-5.48%
Day range:
$24.82 - $26.22
52-week range:
$24.48 - $47.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
81.93x
P/B ratio:
1.84x
Volume:
566.5K
Avg. volume:
1.1M
1-year change:
-28.81%
Market cap:
$2.2B
Revenue:
$23.4M
EPS (TTM):
-$2.33
Analysts' Opinion
-
Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $55.79, IDEAYA Biosciences has an estimated upside of 121.72% from its current price of $25.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $27.00 representing 100% downside risk from its current price of $25.16.
Fair Value
-
According to the consensus of 12 analysts, IDEAYA Biosciences has 121.72% upside to fair value with a price target of $55.79 per share.
IDYA vs. S&P 500
-
Over the past 5 trading days, IDEAYA Biosciences has overperformed the S&P 500 by 0.81% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
IDEAYA Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IDEAYA Biosciences revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter IDEAYA Biosciences reported revenues of --.
Earnings Growth
-
IDEAYA Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter IDEAYA Biosciences reported earnings per share of -$0.60.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
81.93x
EV / EBIT:
--
EV / Revenue:
53.65x
PEG ratio (5yr expected):
-0.31x
EV / Free cash flow:
-8.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $49.9M | $23.5M | -- | $8M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$54.4M | -$119M | -$224.8M | -$33.5M | -$66.9M | |
| EBITDA | -$51.1M | -$115.1M | -$220.5M | -$32.5M | -$65.9M | |
| Diluted EPS | -$1.36 | -$1.95 | -$2.33 | -$0.46 | -$0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $281.3M | $269M | $393.4M | $482.2M | $932.2M | |
| Total Assets | $301.4M | $399.4M | $410.9M | $532.9M | $1.2B | |
| Current Liabilities | $54.2M | $38.6M | $32.7M | $24.9M | $40.7M | |
| Total Liabilities | $106M | $81.8M | $42.1M | $24.9M | $59.5M | |
| Total Equity | $195.4M | $317.6M | $368.8M | $508M | $1.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$80.5M | -$114.8M | -$149.7M | -$30.2M | -$49.2M | |
| Cash From Investing | -$23.5M | -$56.8M | -$417.4M | $51.3M | -$20M | |
| Cash From Financing | $97.5M | $222.1M | $815.7M | $27.8M | $286.5M | |
| Free Cash Flow | -$84.5M | -$116.4M | -$153.3M | -$30.8M | -$49.7M | |
IDYA
Sector
Market Cap
$2.2B
$45.9M
Price % of 52-Week High
52.71%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-28.81%
-32.15%
Beta (5-Year)
0.792
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$25.51
200-day SMA
Sell
Level
$35.90
Bollinger Bands (100)
Sell
Level
26.94 - 36.24
Chaikin Money Flow
Buy
Level
8.8M
20-day SMA
Sell
Level
$26.39
Relative Strength Index (RSI14)
Sell
Level
41.31
ADX Line
Buy
Level
8.4
Williams %R
Buy
Level
-82.0915
50-day SMA
Sell
Level
$27.93
MACD (12, 26)
Sell
Level
-0.78
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
41.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (48.7268)
Buy
CA Score
(Annual)
Level (0.3836)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (4.316)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
Stock Forecast FAQ
In the current month, IDYA has received 11 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IDYA average analyst price target in the past 3 months is $55.79.
-
Where Will IDEAYA Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that IDEAYA Biosciences share price will rise to $55.79 per share over the next 12 months.
-
What Do Analysts Say About IDEAYA Biosciences?
Analysts are divided on their view about IDEAYA Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IDEAYA Biosciences is a Sell and believe this share price will drop from its current level to $27.00.
-
What Is IDEAYA Biosciences's Price Target?
The price target for IDEAYA Biosciences over the next 1-year time period is forecast to be $55.79 according to 12 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IDYA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IDEAYA Biosciences is a Buy. 11 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IDYA?
You can purchase shares of IDEAYA Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IDEAYA Biosciences shares.
-
What Is The IDEAYA Biosciences Share Price Today?
IDEAYA Biosciences was last trading at $25.04 per share. This represents the most recent stock quote for IDEAYA Biosciences. Yesterday, IDEAYA Biosciences closed at $25.16 per share.
-
How To Buy IDEAYA Biosciences Stock Online?
In order to purchase IDEAYA Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 1.85% over the past day.
Sell
50
TSLL alert for Dec 30
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 5.09% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 9.09% over the past day.
